Vaccine candidate against MERS coronavirus reveals efficacy in mouse model
The MERS coronavirus can cause severe, potentially lethal infections in human patients. An authorised vaccine is not available, so far. Researchers at the Paul-Ehrlich-Institut in collaboration with various research groups at the German Center for Infection Research (Deutsches Zentrum für Infektionsforschung (DZIF) have developed a vaccine on the basis of a measles virus vaccine strain. This vaccine is highly immunogenic and challenge experiments indicate protection of vaccinated animals.
Is the eradication of multi-drug resistant bacteria (MRSA and ESBL-E) on pig farms feasible?
Colonisation of livestock with multi-drug resistant bacteria that respond to a limited number of antibiotics is considered as a possible risk factor for the introduction of multi-drug resistant pathogens into the food chain. On a model pig farm, German scientists for the first time demonstrated that extensive disinfection of the stable can be successfully used as a means of eradicating both antibiotic resistant ESBL-E and LA-MRSA from the stable environment.
A global standard for the testing of mycoplasma contamination has been developed
Biological medicinal products such as recombinant proteins, monoclonal antibodies, and many vaccines are produced in cell cultures. Staff members of the Paul-Ehrlich-Institut have taken the lead in developing, on behalf of the WHO, the first internationally recognized reference preparation for tests detecting mycoplasma contamination in cell cultures.